Atlas Trials

Kartos Therapeutics, Inc.

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Kartos Therapeutics, Inc.

RecordFirmDate
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (NCT06479135)Kartos Therapeutics, Inc.2024-06-03
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer (NCT05797831)Kartos Therapeutics, Inc.2023-07-17
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer (NCT05705466)Kartos Therapeutics, Inc.2023-06-01
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT05027867)Kartos Therapeutics, Inc.2021-12-06
KRT-232 and TKI Study in Chronic Myeloid Leukemia (NCT04835584)Kartos Therapeutics, Inc.2021-05-07
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis (NCT04878003)Kartos Therapeutics, Inc.2021-04-13
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL (NCT04502394)Kartos Therapeutics, Inc.2021-02-23
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib (NCT04485260)Kartos Therapeutics, Inc.2021-01-28
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (NCT04640532)Kartos Therapeutics, Inc.2020-11-17
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma (NCT03787602)Kartos Therapeutics, Inc.2019-03-19
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera (NCT03669965)Kartos Therapeutics, Inc.2019-01-15
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (NCT03662126)Kartos Therapeutics, Inc.2019-01-15

Track Kartos Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.